DeepMed Research

Vandetanib

Generic Name: Vandetanib

Brand Names: Caprelsa

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄BrFN_₄O_₂

CAS Number: 443913-73-3

Unique Ingredient Identifier: YO460OQ37K

Background: Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Indication: Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

Associated Conditions: Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer

Clinical Trials

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: FOLFIRI
Drug: Vandetanib

First Posted Date: 2007-03-30

Last Posted Date: 2016-10-07

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 106

Registration Number: NCT00454116

Locations: 🇬🇧
Research Site, Manchester, United Kingdom
🇬🇧
Research site, Belfast, Northern Ireland, United Kingdom

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Terminated

Conditions: Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms

Interventions: Drug: Vandetanib

First Posted Date: 2007-03-09

Last Posted Date: 2012-06-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00445549

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

Phase 1

Completed

Conditions: Glioblastoma Multiforme
Gliosarcoma

Interventions: Drug: ZD6474
Drug: temozolomide
Radiation: Radiation Therapy

First Posted Date: 2007-02-28

Last Posted Date: 2019-03-05

Lead Sponsor: Patrick Y. Wen, MD

Target Recruit Count: 119

Registration Number: NCT00441142

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 4 locations

ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2007-02-16

Last Posted Date: 2012-10-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00436072

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Vandetanib

First Posted Date: 2007-01-05

Last Posted Date: 2024-12-31

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 698

Registration Number: NCT00418886

Locations: 🇻🇪
Research Site, Valencia, Venezuela

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: ZD6474

First Posted Date: 2006-12-12

Last Posted Date: 2015-03-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT00410189

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Malignant Pleural Effusion With ZD6474

Phase 2

Terminated

Conditions: Lung Cancer
Pleural Effusion

Interventions: Drug: ZD6474

First Posted Date: 2006-11-22

Last Posted Date: 2016-03-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00402896

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Vandetanib
Drug: Erlotinib

First Posted Date: 2006-08-15

Last Posted Date: 2018-01-25

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 1574

Registration Number: NCT00364351

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer
Non-small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: Vandetanib

First Posted Date: 2006-04-10

Last Posted Date: 2016-09-30

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 1690

Registration Number: NCT00312377

Locations: 🇻🇳
Research Site, Ho Chi Minh city, Vietnam

Phase II Study of ZD6474 in Advanced NSCLC

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: ZD6474
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-02-13

Last Posted Date: 2016-05-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00290537

Locations: 🇺🇸
University of Texas M.D.Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy